Studies investigating GLP-1 or GLP-1/GIP analogs have demonstrated beneficial effects of these drug classes on reducing liver steatosis and fibrosis, as well as lowering cardiovascular risk [3,5,8,10,11,13]. This evidence concerns the gene GLP1R and Hepatic steatosis.